Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $380
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $370 to $380.
November 07, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $370 to $380.
The raised price target by Cantor Fitzgerald indicates a positive outlook for Vertex Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100